My question to the MND webinar.
Riluzole blocks release of glutamate through reduced synapse formation and subsequent electrical activity.
It has a low grade autophagic component in Beclin 1 and LC3AII.
Monepantel disrupts P13K via the mTOR pathway.
Both P13K and Beclin 1 are responsible for considered autophagy in the human body.
If one was to companion Riluzole and Monepantel together the synergy of P13K and Beclin 1 it may possibly recruit to the mitochondria and golgi apparatus to form an isolated membrane in phagophore through recycling the endosome.
Ref : Oncotarget 2016 Zhan et al
Ref : Impaired autophagy in motor neurones: A final common mechanism of injury and death. Gonzales et al 2018.
- Forums
- ASX - By Stock
- PAA
- Ann: First Patient Dosed in MND Phase 1/2 Trial
Ann: First Patient Dosed in MND Phase 1/2 Trial, page-123
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
|
|||||
Last
17.0¢ |
Change
0.005(3.03%) |
Mkt cap ! $82.65M |
Open | High | Low | Value | Volume |
17.0¢ | 18.0¢ | 16.8¢ | $151.1K | 877.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 54714 | 17.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 371375 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 54714 | 0.170 |
6 | 317468 | 0.165 |
6 | 179000 | 0.160 |
4 | 512800 | 0.155 |
7 | 295666 | 0.150 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 371375 | 7 |
0.185 | 177426 | 2 |
0.190 | 261458 | 4 |
0.195 | 147632 | 3 |
0.200 | 1055496 | 11 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |